DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

DBV Technologies, a clinical-stage biopharmaceutical company focused on developing innovative treatment options for food allergies and other immunologic conditions, has announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference. CEO Daniel Tassé will engage in a fireside chat on November 11, 2025, at 2:00 p.m. ET in Boston, Massachusetts. Attendees will have the opportunity to access a live webcast of this discussion, which will also be archived for 90 days on the Company’s investor website.

DBV Technologies is particularly known for its proprietary VIASKIN® patch technology, a non-invasive approach designed to address food allergies. This mechanism, termed epicutaneous immunotherapy (EPIT), aims to desensitize individuals to allergens by delivering microgram quantities of biologically active compounds through the skin. This method seeks to re-educate the immune system and reduce the severity of allergic reactions, which can vary from mild symptoms to life-threatening anaphylaxis. The company’s ongoing clinical trials include studies targeting peanut allergies in both toddlers (ages 1-3) and young children (ages 4-7).

Headquartered in Châtillon, France, with additional operational presence in Warren, NJ, DBV Technologies is committed to improving the lives of individuals suffering from food allergies, which currently affect millions globally, particularly young children. The company’s stock is traded on Euronext Paris under the symbol DBV and on the Nasdaq Capital Market as DBVT, with its ordinary shares and American Depositary Shares (ADSs) reflecting its commitment to transparent and accessible investor relations. For further information and updates, stakeholders can visit the company’s website and follow its engagements on social media platforms.

As DBV Technologies (Euronext: DBV; Nasdaq: DBVT) prepares for its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference, scheduled for November 11, it presents a timely opportunity for investors to assess the company’s potential. Led by CEO Daniel Tassé, DBV has positioned itself at the forefront of addressing significant unmet medical needs through its innovative therapeutic technologies, particularly its proprietary VIASKIN® patch, designed to treat food allergies.

Investors should focus on several key factors ahead of the conference. First, the increasing prevalence of food allergies and the acute need for effective treatment options underscore the market potential for DBV's products. With millions affected globally, especially among young children, the company's focus on epicutaneous immunotherapy demonstrates a commitment to developing solutions that are not only innovative but also patient-friendly due to their non-invasive nature.

The ongoing clinical trials for the VIASKIN Peanut patch targeting toddlers and children will likely be a focal point during the fireside chat. These trials are crucial as positive results could significantly advance the company's commercialization prospects and enhance investor confidence. As DBV Technologies strives to transform how food allergies are managed, success in these trials could lead to increased market penetration and revenue opportunities.

Moreover, investors should monitor the broader sentiment in the biopharmaceutical industry, which can impact stock performance. Public conferences like the Guggenheim event often serve to showcase innovation, attract potential partnerships, and boost investor interest.

With the potential for heightened visibility and engagement with the investment community, DBV Technologies presents an intriguing option for investors looking for exposure to pioneering advancements in healthcare solutions. Keeping an eye on the outcomes of DBV's clinical trials and the discussions at the conference could offer valuable insights into the firm's future trajectory.